loading page

Safety of Administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 Vaccine in Youths and Young Adults with a History of Acute Lymphoblastic Leukaemia and Allergy to PEG-Asparaginase
  • +7
  • Catherine Mark,
  • Sumit Gupta,
  • Angela Punnett,
  • Julia Upton,
  • Julia Orkin,
  • Adelle Atkinson,
  • Lindsay Clarke,
  • Alice Heisey,
  • Christine McGovern,
  • Sarah Alexander
Catherine Mark
Hospital for Sick Children
Author Profile
Sumit Gupta
The Hospital for Sick Chilren
Author Profile
Angela Punnett
SickKids
Author Profile
Julia Upton
Hospital for Sick Children
Author Profile
Julia Orkin
Hospital for Sick Children
Author Profile
Adelle Atkinson
Hospital for Sick Children, Toronto, Canada
Author Profile
Lindsay Clarke
Hospital for Sick Children
Author Profile
Alice Heisey
Hospital for Sick Children
Author Profile
Christine McGovern
Hospital for Sick Children
Author Profile
Sarah Alexander
Hospital for Sick Children
Author Profile

Abstract

Vaccination is a critical tool in the prevention of COVID-19 infection for individuals and for communities. The mRNA vaccines contain polyethylene glycol (PEG) as a stabilizer. Currently in North America only the BNT162b2 (Pfizer-BioNTech) mRNA vaccine is approved individuals 12 to 17 years of age. Most patients treated with contemporary regimens for acute lymphoblastic leukemia receive Peg-asparaginase and 10-30% will develop allergic reactions. Optimizing access and safety for vaccine administration for these patients critical. This report describes a process developed to support COVID vaccination in a cohort of adolescents and young adults with a history of PEG-asparaginase allergy.

Peer review status:ACCEPTED

27 Jun 2021Submitted to Pediatric Blood & Cancer
27 Jun 2021Submission Checks Completed
27 Jun 2021Assigned to Editor
29 Jun 2021Reviewer(s) Assigned
13 Jul 2021Review(s) Completed, Editorial Evaluation Pending
13 Jul 2021Editorial Decision: Revise Minor
15 Jul 20211st Revision Received
15 Jul 2021Submission Checks Completed
15 Jul 2021Assigned to Editor
19 Jul 2021Reviewer(s) Assigned
28 Jul 2021Review(s) Completed, Editorial Evaluation Pending
02 Aug 2021Editorial Decision: Accept